(Boursier.com) — Eurobio Scientific recorded revenue of €184.1 million in 2021, close to the record level of €188.5 million set in 2020. In a year still very marked by the health crisis, these figures reflect a still very high level of sales related to the diagnosis of COVID (102.6 ME, or 56% of turnover), despite lower prices compared to the previous year.
COVID revenue was down a limited 12% over the year, in a context of a sharp drop in prices linked to the massive arrival of products from Asia, in particular in the antigen testing segment in which Eurobio Scientific is not very present. Eurobio remains one of the main French players in the diagnosis of COVID with large private and hospital laboratories and has continued to increase its installed base of machines, most of which are also used for the group’s non-COVID products.
In 2021, Eurobio saw continued growth in its traditional activities, excluding COVID (81.5 ME, or 44% of turnover).
At the end of 2021, Eurobio Scientific had more than 100 ME of available cash, for a net financial debt of just over 10 ME, the PGE loan having been fully repaid. These significant financial resources allow the group to pursue its strategic development by investing in R&D or in targeted external growth, in order to continue to increase the share of its international sales.
The group specifies that the significant share of sales of proprietary products should make it possible to maintain a good level of results in 2021.
©2022 Boursier.com